ArriVent BioPharma Enters Material Definitive Agreement
Ticker: AVBP · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $615.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, regulation-fd, financial-exhibits
TL;DR
ArriVent BioPharma just signed a big deal, filing an 8-K with material agreements and financial exhibits.
AI Summary
On June 4, 2024, ArriVent BioPharma, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. ArriVent BioPharma, Inc. is incorporated in Delaware and its principal executive offices are located in Newtown Square, PA.
Why It Matters
This filing indicates a significant new agreement for ArriVent BioPharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce significant new risks or opportunities, requiring careful evaluation.
Key Players & Entities
- ArriVent BioPharma, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Newtown Square, PA (location) — Address of principal executive offices
FAQ
What is the nature of the Material Definitive Agreement ArriVent BioPharma entered into?
The filing states that ArriVent BioPharma, Inc. entered into a Material Definitive Agreement on June 4, 2024, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 4, 2024.
In which state is ArriVent BioPharma, Inc. incorporated?
ArriVent BioPharma, Inc. is incorporated in Delaware.
What is the business address of ArriVent BioPharma, Inc.?
The business address of ArriVent BioPharma, Inc. is 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073.
What other information is included in this 8-K filing besides the Material Definitive Agreement?
This 8-K filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 914 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2024-06-05 07:15:53
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share AVBP The Nasdaq
- $615.5 million — stone payments of up to an aggregate of $615.5 million from the Company. Additionally, Alphama
Filing Documents
- tm2416477d1_8k.htm (8-K) — 30KB
- tm2416477d1_ex99-1.htm (EX-99.1) — 13KB
- tm2416477d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-068503.txt ( ) — 223KB
- avbp-20240604.xsd (EX-101.SCH) — 3KB
- avbp-20240604_lab.xml (EX-101.LAB) — 33KB
- avbp-20240604_pre.xml (EX-101.PRE) — 22KB
- tm2416477d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 5, 2024 , the Company issued a press release announcing the multi-target ADC collaboration with Alphamab. A copy of the press release is furnished as Exhibit 99.1 hereto. The information set forth in this Item 7.01 and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated June 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARRIVENT BIOPHARMA, INC. By: /s/ Winston Kung, MBA Winston Kung, MBA Chief Financial Officer and Treasurer Date: June 5, 2024